Changes of sST2 and NT-proBNP levels in patient with acute heart failure and its clinical significance

Gao Ming; Li Lin; Cui Wei

doi:10.3969/j.issn.1674-4055.2019.01.10

Abstract：To explore the changes of serum soluble ST2 receptor (sST2) and N-terminal brain natriuretic peptide (NT-proBNP) in patients with acute heart failure and its clinical significance. Methods A total of 93 patients with acute heart failure admitted to the Third Affiliated Hospital of Henan University of Traditional Chinese Medicine from September 2016 to March 2017 were included in the NYHA class Ⅱ (n=41), NYHA according to the New York Heart Association (NYHA) classification. Grade Ⅲ (n=28) and NYHA grade Ⅳ (n=24), and 40 healthy subjects were randomly selected as the control group. Serum sST2 and NT-proBNP levels were measured by enzyme-linked immunosorbent assay (ELISA). The area under the receiver operating curve (ROC) curve (AUC) was used to evaluate the diagnostic value of sST2 and NT-proBNP for acute heart failure. Heart failure was recorded. The incidence of cardiovascular adverse events within 1 year after discharge from the patient. Results The serum levels of sST2 and NT-proBNP in patients with acute heart failure were higher than those in the control group, and the higher the NYHA classification, the higher the serum sST2 and NT-proBNP levels, the difference was statistically significant (P<0.05). The AUC of serum NT-proBNP was 0.807 (95%CI: 0.723~0.891, P<0.05), and the AUC of serum sST2 was 0.781 (95%CI: 0.694~0.869, P<0.05). The NT-proBNP and sST2 levels were grouped by median. The incidence of cardiovascular adverse events was compared between the two groups. The incidence of cardiovascular adverse events was higher in the NT-proBNP than in the median array (36.54% vs. 14.63%, P<0.05), the incidence of cardiovascular adverse events was higher in the sST2 level than in the median array than in the low level group (28.57% vs. 11.36%, P<0.05). Conclusion Serum sST2 and NT-proBNP are involved in the development and progression of acute heart failure, and early detection can be used as a biomarker for predicting the prognosis of acute heart failure.